Trial of Anti-Tim-3 in Combination With Anti-PD-1 and SRS in Recurrent GBM
Status:
Recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects of stereotactic radiosurgery with MBG453 and
spartalizumab in treating patients with recurrent glioblastoma multiforme (GBM). Stereotactic
radiosurgery is a specialized radiation therapy that delivers a single, high dose of
radiation directly to the tumor to more precisely target the cancer. Monoclonal antibodies,
such as MBG453 and spartalizumab may interfere with the ability of tumor cells to grow and
spread. Giving stereotactic radiosurgery together with immunotherapy may be a better
treatment for GBM.
Phase:
Phase 1
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins